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ABSTRACT 32 
 33 
Human mesenchymal stromal/stem cells (hMSCs) are used in experimental cell therapy to treat various 34 
immunological disorders, and the extracellular vesicles (hMSC-EVs) they produce have emerged as an option 35 
for cell-free therapeutics. The immunomodulatory function of hMSCs resembles the resolution of inflammation, 36 
in which proresolving lipid mediators (LMs) play key roles. Multiple mechanisms underlying the hMSC 37 
immunosuppressive effect has been elucidated; however, the impact of LMs and EVs in the resolution is poorly 38 
understood. In this study, we supplemented hMSCs with polyunsaturated fatty acids (PUFAs); arachidonic acid, 39 
eicosapentaenoic acid, and docosahexaenoic acid, which serve as precursors for multiple LMs. We then 40 
determined the consequent compositional modifications in the fatty acid, phospholipid, and LM profiles. Mass 41 
spectrometric analyses revealed that the supplemented PUFAs were incorporated into the main membrane 42 
phospholipid classes with different dynamics, with phosphatidylcholine serving as the first acceptor. Most 43 
importantly, the PUFA modifications were transferred into hMSC-EVs, which are known to mediate hMSC 44 
immunomodulation. Furthermore, the membrane-incorporated PUFAs influenced the LM profile by increasing 45 
the production of downstream prostaglandin E2 and proresolving LMs, including Resolvin E2 and Resolvin D6. 46 
The production of LMs was further enhanced by a highly proinflammatory stimulus, which resulted in an 47 
increase in a number of mediators, most notably prostaglandins, while other stimulatory conditions had less a 48 
pronounced impact after a 48-hour incubation. The current findings suggest that PUFA manipulations of 49 
hMSCs exert significant immunomodulatory effects via EVs and proresolving LMs, the composition of which 50 
can be modified to potentiate the therapeutic impact of hMSCs.  51 
 52 
 53 
Highlights 54 
 Cell membrane phospholipids of hMSCs accept supplemented PUFAs with different dynamics 55 
 Extracellular vesicle membranes of hMSCs can be modified with PUFA supplementation 56 
 hBMSCs produce proresolving lipid mediators 57 
 PUFA supplementation and inflammatory stimuli impact the lipid mediator profile 58 
 59 
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1. INTRODUCTION 73 
Mesenchymal stromal/stem cells (MSCs) are used for the experimental treatment of immunological disorders, 74 
such as graft-versus-host disease and Crohn’s disease, with promising results [1–3]. However, the clinical use of 75 
these cells is hampered by an insufficient understanding of their mechanisms of function. The MSC mode of 76 
action resembles the resolution of inflammation, i.e., the active dampening of inflammation [4], and they 77 
modulate immune cells by expressing and secreting various factors, such as the tryptophan-degrading enzyme 78 
indoleamine 2,3-dioxygenase [5], adenosine-producing CD73 [6–8], prostaglandin (PG)E2 [9], and extracellular 79 
vesicles (EVs) [10,11]. According to a new intriguing mechanism MSCs are required to undergo apoptosis in 80 
the patient to exert their therapeutic response [12]. Apoptosis is essential for efferocytosis, the clearance of dead 81 
and dying cells, which is carried out by macrophages during the resolution of inflammation [13].   82 
A failure in the resolution of inflammation has been associated with the pathogenesis of inflammatory disorders, 83 
such as inflammatory bowel disease [14] and asthma [15,16]. Different lipid mediators (LMs) play key roles in 84 
different phases of inflammation. PGs are traditionally considered to be proinflammatory LMs, but they also 85 
initiate LM class switching, which results in a decrease in 5-lipoxygenase (LOX)-derived proinflammatory LMs 86 
and an increase in 15-LOX-derived proresolving LMs [17]. The specialized proresolving mediators (SPMs), 87 
which include the resolvins, protectins, maresins, and lipoxins, regulate inflammation at pico- to nanomolar 88 
concentrations by counter-regulating the production of proinflammatory mediators, inducing efferocytosis, and 89 
polarizing macrophages towards a more anti-inflammatory phenotype [18,19]. A myriad of enzymes, including 90 
phospholipases (PLAs), cyclooxygenases (COXs), LOXs, and cytochrome P450s, are involved in LM 91 
biosynthesis from their precursor polyunsaturated fatty acids (PUFAs) [20]. These PUFAs, such as arachidonic 92 
acid (AA), eicosapentaenoic acid (EPA), n-3 docosapentaenoic acid (DPA), and docosahexaenoic acid (DHA) 93 
may be attached in membrane phospholipids (PLs), which can be deliberated from the membrane  prior to the 94 
biosynthesis to LMs [20–25].  95 
The plasma membrane is a dynamic interface between the cell and the environment and the site of intercellular 96 
communication. One of the represented mechanisms of cellular communication is to secrete EVs, which are 97 
surrounded by the PL bilayer and transport a variety of protein and lipid molecules, including PLA2 enzymes, 98 
LMs and their monohydroxy pathway markers [26–31]. These bioactive components of EVs are thought to 99 
regulate immunological responses, and therefore the EVs have been regarded as an option for cell-free 100 
therapeutics [29]. MSC-derived EVs (MSC-EVs) have been shown to elicit similar immunosuppressive 101 
functions to the cells and, thus, have been suggested to mediate the therapeutic effect of MSCs [11,32,33]. 102 
Our research group has previously demonstrated that the membrane n-3/n-6 PUFA ratio correlates with the 103 
functionality of human bone marrow-derived MSCs (hBMSCs), as an increase in n-3 fatty acids was associated 104 
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with an improved immunosuppressive capacity [34]. We have previously shown that the PL profile of hBMSCs 105 
can be modified by PUFA supplementation [35], and others have reported that proinflammatory stimuli may 106 
alter the PL profile [36]. The importance of specific PUFA manipulations on MSC functions has been 107 
highlighted by the findings of Tsoyi and colleagues, who observed that MSCs preconditioned with carbon 108 
monoxide and DHA improved the survival of mice in a sepsis model when compared to cells preconditioned 109 
with carbon monoxide and AA [37]. Moreover, mammalian MSCs have been found to produce SPMs [37–39], 110 
although the data on human MSCs is sparse, reporting only the production of lipoxin A4 (LXA4) [38]. The 111 
hBMSCs have a limited ability to convert C18 PUFAs to the highly unsaturated (4-6 double bonds) C20-22 112 
fatty acids due to their inadequate desaturase activities, and therefore, the cells must acquire the C20-22 PUFA 113 
precursors required for SPM biosynthesis from the environment [35]. 114 
In this study, we investigated the changes in lipid metabolism of hBMSCs and their EVs in response to different 115 
supplemented PUFAs, which serve as precursors for multiple LMs and SPMs. In more detail, we investigated 116 
the dynamics of PUFA incorporation into membrane PLs by monitoring the total fatty acid profile and the 117 
appearance of specific polyunsaturated species into the main PL classes of the cells, i.e., phosphatidylcholine 118 
(PC), phosphatidylethanolamine (PE), and phosphatidylserine (PS). Our aim was to elucidate whether these PL 119 
membrane modifications of hBMSCs would be reflected in the compositions of the EVs they secrete and, 120 
ultimately, the impact of this phenomenon on the LM profiles. Our findings demonstrate that hBMSCs produce 121 
LMs and suggest that their SPM profiles may contribute to hBMSC protective actions. 122 
 123 
2. MATERIALS AND METHODS 124 
2.1 Ethics and bone marrow donors 125 
The Ethical Committee of Northern Ostrobothnia Hospital District or the Ethical Committee of the Hospital 126 
District of Helsinki and Uusimaa approved all the patient protocols. The use of human material conformed to 127 
the principles outlined in the Declaration of Helsinki. After acquiring written consent, aspirates were collected 128 
from the iliac crest or upper femur methaphysis of adult patients. hBMSCs were isolated from the obtained bone 129 
marrow, and primary cell lines were established as previously described [40,41]. 130 
 131 
2.2 Cell culture of hBMSCs 132 
Primary hBMSC lines established from four different donors were used, and passage four cells were thawed and 133 
plated on 10 cm or 15 cm plates (NunclonTM Delta Surface, Thermo Fisher Scientific, Waltham, MA, USA) at a 134 
density of 1,000 cells/cm2. The cells were cultured at 37 °C in a 5% CO2 humidified incubator in proliferation 135 
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medium: minimum essential α-medium (α-MEM) supplemented with 10% fetal bovine serum (FBS), 100 U/mL 136 
penicillin, 100 μg/mL streptomycin, and 20 mM HEPES (all from Thermo Fisher Scientific). The medium was 137 
replaced once during cultivation. The cells were washed with 5 mL Cell Therapy Systems Dulbecco’s 138 
phosphate-buffered saline (DPBS, Thermo Fisher Scientific), detached with 1.5 mL TrypLETM Express 139 
(Thermo Fisher Scientific) when the confluence reached 80%, and passaged once for the following experiments. 140 
The cell number and viability were calculated using a NucleoCounter® NC-100TM (ChemoMetec, Lillerod, 141 
Denmark). 142 
 143 
2.2.1 PUFA incorporation experiments 144 
For the PUFA incorporation experiments, hBMSCs were passaged onto 10 cm plates at a density of 1,000 145 
cells/cm2, and the medium was replaced once during cultivation. The hBMSCs were supplemented with 146 
different PUFAs as previously described [35] when the cultures reached 80–90% confluence. In brief, the initial 147 
medium with 10% FBS was replaced with proliferation medium containing only 5% FBS to limit the fatty acid 148 
content available for the hBMSCs. After the medium change, the cells were supplemented with ethanol (purity 149 
≥ 99.5%, Altia Industrial, Rajamäki, Finland) as a control, or with the PUFAs AA (20:4n-6), EPA (20:5n-3) or 150 
DHA (22:6n-3) (all from Cayman Chemical, Ann Arbor, MI, USA) bound to fatty acid-free bovine serum 151 
albumin (Sigma-Aldrich, St. Louis, MO, USA) at 50 μM final concentration in the cell culture medium. The 152 
PUFA stock solutions were made in ethanol. The PUFA-supplemented cell cultures were incubated at 37 °C in 153 
a 5% CO2 humidified incubator. Following incubations of 2, 6, and 24 h, the cells were washed two times with 154 
5 mL cold PBS (Sigma-Aldrich), harvested, snap frozen, and stored at -70 °C. 155 
 156 
2.2.2 hBMSC-EV experiments 157 
For the collection of EVs, hBMSCs were passaged into the two-chamber type of Corning® CellSTACK® cell 158 
culture chambers (Sigma-Aldrich) at a density of 1,000 cells/cm2 in 250 mL proliferation medium. Half of the 159 
medium was replaced once. When they had reached 80–90% confluence, the hBMSCs were first supplemented 160 
with PUFAs for 24 h as described in section 2.2.1, and then they were washed three times with 100 mL DPBS 161 
and one time with 75 mL a-MEM. The cells were then incubated for 48 h in 200 mL serum-free α-MEM, 162 
detached with 33.7 mL TrypLETM Express and collected as described above. The conditioned cell culture 163 
medium was centrifuged at 2,000 g for 10 min to remove cell debris. The supernatant was ultracentrifuged with 164 
an OptimaTM MAX-XP Ultracentrifuge (Beckman Coulter, Indianapolis, IN, USA) at 100,000 g for 2 h +4 °C 165 
using a MLA-50 rotor (k-factor = 92, Beckman Coulter). The pelleted EVs were suspended to PBS and 166 
combined. The samples were further ultracentrifuged at 100,000 g for 2 h +4 °C using a MLS-50 rotor (k-factor 167 
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= 71, Beckman Coulter) and suspended in 100 μL PBS or Millipore water for mass spectrometric analysis and 168 
immunoblotting, respectively. A 10 μL aliquot was transferred to Protein LoBind tubes (Eppendorf, Hamburg, 169 
Germany) for Nanoparticle Tracking Analysis. The samples were immediately snap frozen and stored at -70 °C. 170 
 171 
2.2.3 hBMSC incubations for lipid mediator analysis 172 
For the LM analysis, hBMSCs were cultured as for the EV collection described above but passaged onto 10 cm 173 
plates with 10 mL proliferation medium. The cells were supplemented with the different PUFAs for 24 h, 174 
washed three times with 7 mL DPBS, and then incubated for 48 h in 9 mL of serum-free α-MEM. Cells 175 
supplemented with AA and DHA were also incubated under the 4 stimulatory conditions for 48 h in serum-free 176 
medium after PUFA supplementation. Condition 1, transforming growth factor (TGF)-β1 (Thermo Fisher 177 
Scientific) 5 ng/mL and interleukin (IL)-10 (Thermo Fisher Scientific) 10 ng/mL, an anti-inflammatory 178 
stimulus; Condition 2, interferon (IFN)-γ (Sigma-Aldrich) 25 ng/mL and lipopolysaccharide (LPS, Sigma-179 
Aldrich) 10 ng/mL, induces regulatory macrophage polarization [42]; Condition 3, IFN-γ 10 ng/mL and tumor 180 
necrosis factor (TNF)-α (STEMCELL Technologies, Vancouver, BC, Canada) 15 ng/mL, a classical licensing 181 
stimulus, which primes MSCs to become effective immunomodulatory cells [43]; Condition 4, TNF-α 10 182 
ng/mL, IL-1β 10 ng/mL (Sigma-Aldrich), and LPS 100 ng/mL, a very powerful inflammatory stimulus with a 183 
high amount of LPS, which has been shown to affect SPM production in a co-culture of neutrophils and 184 
choroid-retinal endothelial cells [44]. The cell incubations (including cells and conditioned media) were 185 
collected, snap frozen, and stored at -70 °C. 186 
 187 
2.3 EV quantification and size determination 188 
The particle concentration and size distribution of EV samples was determined using Nanoparticle Tracking 189 
Analysis. Data were recorded using camera level 14, and 3 videos of 90 seconds were recorded, manually 190 
mixing the sample with a syringe between measurements. If necessary, the samples were diluted with 0.2 µm 191 
filtrated PBS. Data analysis was performed with a threshold of 5 and gain of 10. The used LM14C model was 192 
equipped with a 70 mW violet (405 nm) laser (Malvern Instruments Ltd., Malvern, UK) and sCMOS camera 193 
(Hamamatsu Photonics K.K., Hamamatsu, Japan), and the data were recorded and analyzed with NanoSight 194 
software version 3.0 (Malvern Instruments Ltd.). 195 
 196 
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2.4 Immunoblotting 197 
hBMSC-EV pellets from control treatment were prepared for Western blot analysis by drying the EV 198 
suspensions with SavantTM SPD111V SpeedVacTM Concentrator (Thermo Fischer Scientific) and suspending 199 
the pellets in 15 µL DPBS containing cOmplete Mini EDTA-free Protease Inhibitor Cocktail (Roche, Basel, 200 
Switzerland), prepared by dissolving 1 tablet of the inhibitor in 10 mL of DPBS. Due to a small amount of 201 
sample material, EV samples were loaded with an equal volume. Platelet-derived EVs were used as controls, 202 
and 30 µg of the controls were loaded onto the gels. The samples were prepared with 4x Laemmli sample buffer 203 
(Bio-Rad, Hercules, CA, USA) containing 10% 2-mercaptoethanol (Sigma-Aldrich) and boiled for 5 min. Then, 204 
the samples were loaded onto Mini-PROTEAN TGX Stain-Free protein gels with a 4-20% gradient (Bio-Rad) 205 
together with Precision Protein Plus WesternC Blotting Standard (Bio-Rad). The gels were run for 50 min at 206 
170 V in 1× Tris/Glycine/SDS Buffer (Bio-Rad), and the proteins were blotted for 20 min with 1.3 A up to 25 V 207 
using a semi-dry blotting machine Trans-Blot Turbo (Bio-Rad), 1× Transfer Buffer (Bio-Rad) including 20% 208 
methanol (Merck, Darmstadt, Germany), and Trans-Blot Turbo Mini Nitrocellulose Transfer Packs (Bio-Rad), 209 
where the original 0.2 µm nitrocellulose membrane was replaced with a 0.45 µm nitrocellulose membrane (Bio-210 
Rad). Transfer of the proteins was confirmed by imaging the gels and membranes using the ChemiDoc Touch 211 
Imaging System (Bio-Rad), followed by 1 h of membrane blocking at room temperature with 6% milk solution 212 
(Valio, Helsinki, Finland) prepared in 1 × Tris-buffered saline (Sigma-Aldrich) containing 0.05% Tween20 213 
(Sigma-Aldrich). 214 
Antibodies against CD9 (Becton Dickinson, Franklin Lakes, NJ, USA, clone M-L13), CD41 (Beckman Coulter, 215 
clone sz22), CD63 (Becton Dickinson, clone H5C6), CD73 (Abcam, Cambridge, UK, ab124725), cytosolic 216 
PLA2 (cPLA2, Abcam, ab58375), and secretory PLA2 (sPLA2, Abcam, ab23705) were diluted 1:250 (CD9 and 217 
CD63), 1: 1:500 (cPLA2), 1:1000 (CD73, sPLA2), or 1:10000 (CD41) in 1 × Tris-buffered saline containing 2% 218 
milk and 0.05% Tween20 and incubated overnight. The membranes were first rinsed and then washed with 219 
Tris-buffered saline containing 0.05% Tween20 3 × 10 min followed by incubation with goat anti-mouse or 220 
anti-rabbit IgG (H + L)-HRP conjugated secondary antibodies (Bio-Rad) containing Precision Protein 221 
StrepTactin-HRP Conjugate (Bio-Rad) diluted 1:3000 and 1:10000, respectively, to Tris-buffered saline 222 
containing 2% milk and 0.05% Tween20. After incubation, the membranes were first rinsed and then washed 2 223 
× 10 min in Tris-buffered saline containing 0.05% Tween20 and 10 min in Tris-buffered saline, followed by the 224 
addition of 1 mL of Amersham ECL Western Blotting Detection Reagent (GE Healthcare, Chicago, IL, USA) 225 
per membrane, mixed 1:1 as instructed. After a 1-min incubation at room temperature, the chemiluminescence 226 
of the membranes was captured using the ChemiDoc Touch Imaging System. 227 
 228 
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2.5 Fatty acid analysis  229 
Fatty acids of hBMSCs were identified and quantified from transmethylated lipid extracts as described 230 
previously [35]. Cell samples supplemented with PUFAs for 2, 6, and 24 h were extracted according to Folch et 231 
al. [45], evaporated into dryness under a nitrogen gas stream, and transmethylated as recommended by 232 
Christie[46]. In brief, the samples were heated in 1% H2SO4 (Sigma-Aldrich) in methanol (LiChrosolv®, 233 
Merck) at a temperature of 96 °C under a nitrogen atmosphere for 120 min. The fatty acid methyl esters 234 
(FAMEs) formed were recovered with hexane (LiChrosolv®, Merck) in two steps, dried overnight in anhydrous 235 
Na2SO4 (EMSURE®, Merck), and analyzed using a gas chromatograph (Shimadzu GC-2010 Plus, Kyoto, 236 
Japan) equipped with an auto injector (AOC-20i), flame ionization detector (FID), and ZB-wax capillary 237 
column (30 m, 0.25 mm ID, 0.25 μm film, Phenomenex, Torrance, CA, USA). The FAME identification was 238 
based on the retention time, use of authentic standard mixtures of known composition and confirmatory 239 
recordings of mass spectra (GC-2010 Plus with GCMS-QP2010 Ultra, Shimadzu, equipped with a similar 240 
column as in the GC-FID system). Quantifications were based on FID responses, which were corrected 241 
according to the theoretical response factors [47] and calibrations with quantitative FAME standards (Supelco, 242 
Bellefonte, PA, USA). The fatty acid proportions were calculated as the mol%, and the fatty acids were marked 243 
using the following abbreviations: [carbon number]:[number of double bonds] n-[position of the first double 244 
bond calculated from the methyl end] (e.g., 22:6n-3 for DHA). 245 
 246 
2.6 Phospholipid profiling  247 
Total lipids of hBMSCs and hBMSC-EVs were extracted using the Folch method [45]. The lipid extracts were 248 
studied by direct infusion electrospray ionization-tandem mass spectrometry (ESI-MS/MS) as previously 249 
described [35] using Agilent 6490 Triple Quad LC/MS with iFunnel technology (Agilent Technologies Inc., 250 
Santa Clara, CA, USA). In brief, the final lipid extracts in chloroform:methanol (1:2, v:v) (both LiChrosolv®, 251 
Merck) spiked with 7 internal standards [PC 14:1/14:1, PC 20:1/20:1, PC 22:1/22:1; PE 14:0/14:0 and 252 
16:1/16:1, PS 14:0/14:0, and sphingomyelin (SM) 18:1/17:0 (all from Avanti Polar Lipids, Alabaster, AL, 253 
USA)] and 1% NH4OH (Surprapur®, Merck) were infused into the MS at a flow rate of 10 µL/min. Specific 254 
precursor ion scans m/z 184 for PC and SM and neutral loss scans of 141 amu for PE, and 87 and 185 amu for 255 
PS, were employed to profile the membrane PL composition [48]. The spectra were processed using 256 
MassHunter Qualitative Analysis software (Agilent Technologies, Inc.), and the individual lipid species were 257 
quantified using the internal standards and free software called Lipid Mass Spectrum Analysis [49]. The acyl 258 
chain assemblies in each lipid species were identified in our previous analytical work on the hBMSCs (cultured 259 
for 9 days with different PUFA supplements) by detecting anionic fragments of the acyl chains [35]; however, 260 
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the species in the present work are marked as follows: [sum of acyl chain carbons]:[sum of acyl chain double 261 
bonds] (e.g., 38:4 for species 18:0_20:4n-6). The results are described as mol% of each lipid species in its PL 262 
class, and the species exceeding 1.0 mol% are included in the figures.  263 
 264 
2.7 Lipid mediator profiling  265 
Incubations of hBMSCs were thawed on ice and 2 volumes of ice-cold methanol (Thermo Fisher Scientific) 266 
containing the internal standards d8-5S-hydroxyeicosatetraenoic acid (HETE), d5-resolvin D2 (RvD2), d5-LXA4, 267 
d4-PGE2, and d4-leukotriene B4 (all from Cayman Chemical), 500 pg each, was added to the sample. LMs were 268 
extracted and identified as described previously [50,51]. Briefly, the samples in methanol were incubated for 45 269 
min at -20 °C for protein precipitation and centrifuged at 1900 g at 4 °C for 10 min. The methanol content of the 270 
supernatant was evaporated to less than 1 mL using a nitrogen gas stream, and the LMs were extracted with an 271 
automated Extra-Hera system (Biotage, Uppsala, Sweden) employing solid-phase extraction. The methyl 272 
formate eluates were concentrated and injected into the liquid chromatography-tandem mass spectrometry (LC-273 
MS/MS) system (LC-20AD HPLC (Shimadzu) and SIL-20AC autoinjector (Shimadzu) paired with QTrap 274 
6500+ (ABSciex, Framingham, MA, USA) or QTrap 5500 (ABSciex). LMs were identified and quantified 275 
using multiple reaction monitoring of the precursor (Q1) and product (Q3) ions in negative ionization mode. 276 
Identification was conducted in accordance with published criteria, matching the retention time with authentic 277 
and synthetic standards (from Cayman Chemical, prepared in house or provided by Charles N. Serhan, Harvard 278 
Medical School, Boston, MA, USA) and identifying at least 6 diagnostic ions from the MS/MS spectra [50,51]. 279 
 280 
2.8 Statistical analysis 281 
Nonparametric tests were applied due to the non-normal distribution of variables, and in cases with a low 282 
number of biological replicates, statistical tests were not conducted. When applicable, the results are expressed 283 
as medians with ranges or interquartile ranges depending on the number of biological replicates. The variation 284 
in fatty acid data at the 2, 6, and 24-h time points was analyzed using the Kruskal-Wallis test and ordered trends 285 
using the Jonckheere-Terpstra test. The analyses were conducted using IBM SPSS Statistics (Version 24), and 286 
p-values < 0.05 were considered statistically significant. The fold changes of the PL and LM data were 287 
determined by calculating the ratio of the values from the PUFA supplementation to those of the control 288 
treatment in biological replicates of each primary cell line. Principal component analysis (PCA) was conducted 289 
and visualized with centered and scaled PL mol% data (all lipid species per PL class were used as variables) 290 
and LM metabolome data as pg / incubation using R version 3.5.1 with the ggbiplot package [52,53]. 291 
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 292 
3 RESULTS 293 
3.1 The incorporation dynamics of supplemented PUFAs differ between hBMSC membrane PLs  294 
Supplementation with the PUFAs AA, EPA, and DHA showed their successful incorporation into the fatty acid 295 
profile (Fig. 1) and membrane PLs (Supplementary Figs. 1-3) after 2, 6, and 24 h of incubation. The specific 296 
PUFA supplementations resulted in an increase in the corresponding PUFAs, especially at the 24-h time point 297 
(Fig. 1 and Supplementary Table 1). Additionally, both AA (20:4n-6) and EPA (20:5n-3) supplementation 298 
caused an accumulation of the elongated forms of these PUFAs: adrenic acid (ADA, 22:4n-6) and n-3 DPA 299 
(22:5n-3), respectively. The PUFA supplementation caused a diminishing trend in the levels of both saturated 300 
and monounsaturated fatty acids (MUFAs) compared with the control. Moreover, AA supplementation 301 
decreased the levels of the n-3 PUFAs DPA ~0.55-fold and DHA ~0.45-fold when compared to the control. In 302 
contrast, both EPA and DHA supplementation decreased the levels of the n-6 PUFAs AA and ADA (EPA: 303 
~0.50- and ~0.61-fold decrease, DHA: ~0.65- and ~0.54-fold decrease in AA and ADA, respectively). EPA 304 
supplementation also decreased the levels of DHA ~0.36-fold. 305 
Incorporation of the exogenous PUFAs was also detected in the hBMSC PL species profiles, but the SMs 306 
species profiles of the cells were mainly unaffected by the supplementation (Fig. 2 and Supplementary Figs. 1-307 
3). Extensive PUFA incorporation into the PC, PE, and PS classes was achieved after a 24-h incubation; 308 
however, different PL classes accepted the supplemented PUFAs with different dynamics (Fig. 2). The 309 
incorporation into PC was already visible after 2 h and increased steadily over time. In PE, the effect was 310 
observed to some extent at 6 h and clearly after 24 h. In the PS species profile, PUFA incorporation was only 311 
observed in the 24-h incubation and was limited to the polyunsaturated C40 species, which showed increased 312 
proportions. 313 
 314 
3.2 PUFA modifications of hBMSC PL membranes are transferred to hBMSC-EVs 315 
We investigated the hBMSC-EVs collected after cultivation of cells with PUFAs (24 h) and subsequently in 316 
serum-free medium (48 h). Neither the amount nor the size distribution of the particles in hBMSC-EV samples 317 
were altered by the PUFA supplementation (Fig. 3A and B). The hBMSC-EVs expressed the MSC surface 318 
marker CD73, while the expression of other markers tested (tetraspanins CD9 and CD63, platelet marker CD41, 319 
cPLA2, and sPLA2) was negligible (Fig. 3C and Supplementary Fig. 4). We profiled the membrane PL 320 
composition of the hBMSC-EVs (Fig. 4B), which corresponded to the PL profile of the donor cells (Fig. 4A) 321 
with certain changes. In PC, di-PUFA species comprising two long and polyunsaturated acyl chains were found 322 
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enriched in EVs compared to the donor cells after PUFA supplementation (e.g., cells: ~2-fold and EVs: ~15-323 
fold increase in the 42:10 species after EPA supplementation). Moreover, after AA and EPA supplementation, 324 
the levels of the 36:1 species, harboring saturated fatty acids and MUFAs, were decreased less in hBMSC-EVs 325 
than in the cells (EVs: ~0.73-fold and ~0.79-fold decrease following AA and EPA supplementation, and in the 326 
cells: ~0.45-fold and ~0.69-fold decreases, respectively). The changes in the PE species profile resembled those 327 
found in the PCs: the di-PUFA species were present with higher proportions in EVs than in the cells (e.g., an 328 
increase in the relative amount of 42:10 after AA supplementation in cells of ~2.4-fold and in EVs up to ~4.7-329 
fold), and the levels of 36:1 (18:0_18:1 chains) did not decrease in the AA and EPA-supplemented hBMSC-330 
EVs despite a clear decrease in the donor cells (AA supplemented cells: ~0.56-fold, EPA supplemented cells: 331 
~0.76-fold decrease). In PS, the species containing C22 ADA, n-3 DPA, and DHA chains (40:4, 40:5, and 40:6, 332 
respectively) were present in cells at higher proportions than in their EVs after the corresponding PUFA 333 
supplementation (cells: ~5.5-, ~5.1-, and ~2.6-fold increase, EVs: ~2.1, ~1.8-, and ~1.6-fold increase in 40:4, 334 
40:5, and 40:6, respectively).  335 
 336 
3.3 Incorporated PUFAs alter the downstream lipid mediator profile of hBMSCs 337 
Incubations of hBMSCs, pre-cultured for 24 h with the PUFA supplements and then incubated for 48 h in 338 
serum-free medium, were studied to examine the LM profile. The hBMSCs produced multiple LMs that were 339 
identified employing previously published criteria by matching the retention times (Fig. 5A) and a minimum of 340 
6 diagnostic ions from the MS/MS spectra of the analyzed mediators with corresponding authentic or synthetic 341 
standards (Fig. 5B) [50,51]. We observed trends that PUFA supplementation increased the production of 342 
downstream LMs and monohydroxy pathway markers even though there were variation in the profiles of 343 
primary hBMSCs from different donors (Fig. 5C and Supplementary Table 2). Assessment of the LM profiles 344 
using multivariate analysis demonstrated that the supplementation of hBMSCs with different PUFAs resulted in 345 
characteristic LM profiles, as depicted by the distinct clusters (Fig. 6). In more detail, AA supplementation 346 
increased the production of PGD2, PGE2, and PGF2α, and EPA supplementation increased the production of 347 
RvE2, while RvE3 provided variable results between individuals. DHA supplementation increased the levels of 348 
RvD4 and RvD6. All supplementations increased the levels of the corresponding monohydroxy pathway 349 
markers, and DHA supplementation also increased the production of hydroxyeicosapentaenoic acids (HEPEs). 350 
 351 
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3.4 hBMSC lipid mediator profiles are regulated in a stimulus-dependent manner 352 
We investigated the effects of stimulatory conditions on LM production by hBMSCs supplemented with AA 353 
and DHA for 24 h. hBMSCs were then cultured under one anti-inflammatory condition: TGF-β1 5 ng/mL and 354 
IL-10 10 ng/mL (Condition 1), and three proinflammatory conditions: IFN-γ 25 ng/mL and LPS 10 ng/mL 355 
(Condition 2); IFN-γ 10 ng/mL and TNF-α 15 ng/mL (Condition 3); or TNF-α 10 ng/mL, IL-1β 10 ng/mL, and 356 
LPS 100 ng/mL (Condition 4) for 48 h. The production of certain LMs and their monohydroxy pathway 357 
markers increased in the stimulatory conditions compared with the control treatment, however, there were 358 
variation in the LM profiles from different hBMSC donors (Fig. 7 and Supplementary Table 3). PGE2 levels 359 
increased considerably under Conditions 1 (~8.7-fold), 3 (~8.6-fold), and 4 (~116-fold) in AA-supplemented 360 
cells, and under Condition 4 (~221-fold) in DHA-supplemented cells when compared to the control. With both 361 
supplements, Condition 4 increased the production of other prostaglandins, PGD2 and PGF2α, and the 362 
monohydroxy pathway markers HETEs (~5-fold and 11.3-fold increase with AA and DHA, respectively) and 363 
hydroxydocosahexaenoic acids (HDHAs) (~2.1-fold and 2.3-fold increase with AA and DHA, respectively). 364 
Moreover, the levels of total SPMs increased with different supplementations, notably in Condition 4 (AA 365 
supplementation ~3.1-fold, and DHA supplementation ~2.2-fold increase) and Condition 3 (AA 366 
supplementation ~4.7-fold increase, while DHA supplementation resulted in ~0.8-fold decrease). Condition 3 367 
had a marked impact on RvD4 production by increasing these levels in both AA and DHA-supplemented cells.  368 
 369 
4. DISCUSSION 370 
In this study, we established that the PL composition of hBMSC-EVs can be modified by supplementing their 371 
donor cells with PUFAs. The incorporation of exogenous PUFAs had different dynamics depending on the 372 
receiving PL class, as revealed in the 2, 6, and 24-h supplementations. The supplemented PUFAs first 373 
incorporated into PC, later into PE, and finally into PS. More importantly, we demonstrated that hBMSCs 374 
translate the changes in their membrane PL profile to their EVs and produce a variety of SPMs that are 375 
modified by the different PUFA supplements and inflammatory stimuli.   376 
The overall PL profile of the control hBMSCs was consistent with our and other’s previous reports [34–36]. 377 
Moreover, the fatty acid profile and the PL species composition following incubation with PUFAs were in 378 
accord with our previous work assessing later time points [35], and the most prominent incorporation of PUFAs 379 
was observed after 24 h of supplementation. In hBMSCs, AA was elongated into ADA, plausibly to limit the 380 
formation of highly bioactive downstream LMs [54,55]. ADA has been reported to elicit lower COX activity 381 
than AA, and thus the conversion to downstream LMs is less effective [54,55]. Moreover, EPA was elongated 382 
into n-3 DPA, which is also a precursor for multiple SPMs, and thereby the n-3 PUFA precursor pool was 383 
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potentially altered towards an even more proresolving LM profile and cell signaling [22,25]. Additionally, due 384 
to the competition of n-3 and n-6 PUFAs for the same elongation and desaturation enzymes, AA 385 
supplementation reduced the levels of n-3 DPA and DHA, while both EPA and DHA reduced the levels of AA 386 
and ADA [56–58]. Mammalian cells use two main pathways for fatty acid incorporation into their PLs, the de 387 
novo Kennedy and remodeling Lands pathways. The latter process gives rise to the most preferred acyl 388 
combinations, often demonstrating saturated fatty acids or MUFAs in the sn-1 position and PUFAs in the sn-2 389 
position of the molecule [59]. Here, we observed the formation of di-PUFA PL species presumably generated 390 
via the Kennedy pathway. This pathway has little positional preference for certain fatty acid structures and may 391 
also give rise to di-PUFA PL species, and it becomes important when the fatty acid concentration in the culture 392 
medium is in the μM range, and the Lands pathway is saturated [60]. 393 
 394 
Interestingly, we observed that the PUFA incorporation rates differed between the PL classes: the supplemented 395 
PUFAs incorporated first into PC and only later into PE and PS, while the SM class, which is in principle poor 396 
in PUFAs, remained largely unaffected. Efficient incorporation of the supplemented PUFAs into the PC species 397 
was already observed at 2 h, which is in agreement with findings from metabolic studies showing that in the 398 
low-capacity/high-affinity Lands cycle, lysoPC acyltransferases transfer the supplemented PUFAs to lysoPC, 399 
which serves as the first acceptor [60,61]. The PE species showed incipient remodeling at 6 h, which continued 400 
at the 24-h time point. Coenzyme A-independent remodeling enzymes, transacylases, transfer PUFAs from PC 401 
to PE, which may take several hours in primary cell lines but occurs in minutes in cancer cell lines [62–64]. A 402 
marked exception to the general observation of detecting elevated levels of the PE species with the 403 
supplemented PUFAs was the PE species 38:4 (mostly 18:0_20:4n-6, determined in our previous study [35]). 404 
The relative proportion of this biologically very active species, which provides AA to PLAs, is maintained at a 405 
constant 20 mol% irrespective of the incubation time with AA, perhaps to limit excess inflammatory signaling 406 
due to PGE2 and other mediators produced from AA. Remodeling of the PS species was delayed the most, 407 
likely because they received their PUFAs mainly from PCs via transacylases between the 6 and 24-h time 408 
points, and direct biosynthesis via the Kennedy pathway was negligible since di-PUFA PS were undetectable. 409 
At 24 h, the chain elongation of PUFA precursors was highly progressed, and little AA or EPA was 410 
incorporated into PS, consisting mainly of only the elongated ADA and n-3 DPA. The incorporation of DHA 411 
was efficient among the PC, PE and PS species, but the relative amounts of di-PUFA species with DHA 412 
remained small. This finding suggests that DHA is not utilized to the same extent as AA or EPA in the Kennedy 413 
pathway. However, the reasons limiting the use of DHA for building di-PUFA species are unclear.  414 
 415 
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Next, we investigated the effects of PUFA modifications on hBMSC-EV membranes at the 24-h time point, 416 
when the PUFAs were already incorporated into several PL classes. The PUFA supplementation had no effect 417 
on the amount of particles secreted or their size distribution. The hBMSC-EVs expressed the cell surface 418 
marker CD73 but the expression of tetraspanins CD9 and CD63, existing typically in the endosomal 419 
compartment, was negligible. These results are in agreement with our previous findings that constitutively 420 
produced umbilical cord blood-derived MSC-EVs lacked the expression of these tetraspanins and expressed 421 
specific Rab proteins, which indicated that these EVs would originate mainly from cell surface [33]. Taken 422 
together, these observations suggest that most EVs secreted by hBMSCs during starvation are derived from the 423 
cell surface.  424 
The lipidome of hBMSC-EVs has previously been characterized in two reports. Vallabhaneni and colleagues 425 
demonstrated that hBMSC-EVs contain ceramides and diacylglycerols that were not investigated in this study 426 
[65]. Haraszti and colleagues were the first researchers to fully profile the PL species composition of hBMSC-427 
EVs [66]; however, comparison of their results with ours is challenging due to differences in the reporting 428 
formats [66]. To our knowledge, we are the first group to demonstrate that modifications of the cell membranes 429 
can be transferred to the PL profile of hBMSC-EVs. The PL composition of the EVs resembled those of the 430 
cells, but with specific differences. The observed larger proportions of di-PUFA species of PC and PE in EVs 431 
compared with cells may arise from the high efflux propensity of these PLs, making them preferred substrates 432 
for PLA2 type IVA cleaving PUFAs for the biosynthesis of LMs [67]. The higher levels of these di-PUFAs in 433 
hBMSC-EVs may enable more efficient biosynthesis of LMs due to the more abundant precursor availability. 434 
Additionally, previous studies have reported the accumulation of monounsaturated acyl chains, mainly due to an 435 
enrichment of 18:1, in the EV PL composition (reviewed recently by Skotland et al. [68]). Our study confirmed 436 
this observation since PE 36:1 and PS 36:1, both of which contain 18:1, were present in higher relative amounts 437 
in EVs than in the donor cells. Certain PL species plausibly move to EVs readily due to their high efflux 438 
propensities and their superior compatibility to the high curvature of the EV membrane, which may explain the 439 
differences in PL species composition between EVs and the corresponding cell membranes. 440 
After demonstrating that both hBMSCs and hBMSC-EV membranes incorporate vital precursors for SPMs, we 441 
further investigated the effects of these PUFA modifications on LM production. To allow relevant comparisons, 442 
we maintained the same experimental conditions as used for the EV membrane PL profiling. The main LM 443 
molecule produced by hBMSCs was PGE2, which coincides with previous reports of PGE2 as a central mediator 444 
of the therapeutic potential of MSCs [9,35,69,70]. Traditionally, PGE2 has been classified as a proinflammatory 445 
mediator, but recent reports have linked it to multiple anti-inflammatory functions [9,58,69]. Interestingly, 446 
PGE2 has also been found to induce LM class switching, a process that is vital for the induction of resolution 447 
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[17], which merits investigation in light of the immunomodulatory response of hBMSCs [70]. Moreover, 448 
studies on SPM production by MSCs are lacking, the majority of which have focused on murine MSCs [37,39], 449 
and only LXA4 has been reported to be produced by human MSCs [38]. A major finding of our study was that 450 
hBMSCs produced a variety of SPMs, including 15-epi-LXA4, RvE2, RvD4, and RvD6, even in the absence of 451 
PUFA supplementation. Recently, we have reported that the level of secreted PGE2 is enhanced in hBMSCs due 452 
to precursor AA supplementation [35]. Here we observed the same trend, in which precursor PUFA 453 
supplementation increased the production of downstream LMs in hBMSCs. Several studies have demonstrated a 454 
potentiated immunological phenotype following EPA or DHA supplementations [e.g., 37, 39, 71]. Interestingly, 455 
Abreu and colleagues recently demonstrated that EPA supplementation enhanced the therapeutic influence of 456 
BMSCs in asthmatic mice [39]. These observations highlight the importance of maintaining an optimal cell 457 
membrane fatty acid profile, which forms the precursor pool for LM biosynthesis. Since hBMSCs have an 458 
incomplete ability to metabolize C18 PUFA precursors to C20-22 PUFAs such as EPA and DHA, 459 
supplementing these precursors of SPMs during cell culture is essential to ensure the full therapeutic potential 460 
of the cells and their EVs [35].  461 
The microenvironment and stimulatory conditions have profound effects on the immunomodulatory capacity of 462 
MSCs [4]. Here we exposed the AA and DHA-supplemented hBMSCs to anti- (Condition 1) and 463 
proinflammatory conditions (Conditions 2-4) to investigate the effects of these stimuli on SPM production. The 464 
effects of the given stimuli may have diminished by the end of our long (48 h) experimental window, which was 465 
initially chosen to correspond to the EV experiments, hence possibly hindering the detection of differences in 466 
LM production and also contributing to the variation observed in these results. Nonetheless, we observed 467 
moderate effects in LM production under Conditions 1-3 and a clear effect to PGs under Condition 4 regardless 468 
of the supplemented PUFA. Condition 4, with a high concentrations of LPS, is known to induce excessive Toll-469 
like receptor 4 activation, and in this study resulted in a pronounced increase in PGs, potentially leading to a 470 
counter-regulatory action by also increasing the production of total SPMs and their precursors/pathway markers 471 
such as 15-HETE and 17-HDHA. As mentioned, the incubation time of the stimuli was long, and possibly, the 472 
initial response of the cells to the inflammatory stimuli may have already dampened after the 48-h incubation. 473 
Thus, the effects of the lower-grade stimuli (Conditions 1-3) to the LM production should be interpreted with 474 
caution due to the experimental setup. Even though the PL profiles of membranes in different primary hBMSCs 475 
remained stable, the observed variation in the LM results may arise due to differences in the activities of the 476 
biosynthetic enzymes of different hBMSC donors. Despite of these limitations, the key finding that hBMSCs 477 
produce SPMs stands firm. Taken together, we were able to elucidate that hBMSCs produce SPMs with and 478 
without an inflammatory stimulus, which has not been demonstrated prior to this study.  479 
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MSCs are known to modulate the responses of various immune cells towards a more anti-inflammatory and 480 
immunosuppressive direction by, e.g., inhibiting the proliferation of T and B cells [72]. MSCs and MSC-EVs 481 
also modulate macrophages towards an anti-inflammatory and even proresolving phenotype [69,73]. It is 482 
important to note that proresolving processes are not immunosuppressive and, thus, do not inhibit the function 483 
of immune cells but rather promote the active return of homeostasis [74,75]. By elucidating the proresolving 484 
properties of MSCs, we may, therefore, uncover novel mechanisms underlying the MSC immunomodulatory 485 
properties, thus raising interest especially in trauma healing. We hypothesize that MSCs can act as promoters of 486 
resolution: by producing PGE2, inducing LM class switching and secreting SPMs, MSCs may promote the onset 487 
of resolution. By increasing SPM production with PUFA supplementation, we are able to reinforce these MSC 488 
actions. The SPM content of hBMSC-EVs remains unknown, but it is tempting to speculate that hBMSC-EVs 489 
can act as inducers of SPM biosynthesis in other immune cells by carrying the raw material (PUFA-modified 490 
PLs) for their SPM biosynthesis. This idea is supported by a previous report, in which neutrophil-derived EVs 491 
were demonstrated to improve the biosynthesis of SPMs of acceptor macrophages [28]. 492 
To conclude, our results demonstrate that the PL composition of hBMSC membranes can be specifically 493 
modified and that these modifications are reflected by parallel modifications in the PL composition of hBMSC-494 
EVs. When hBMSCs were supplemented with immunologically potent PUFAs, alterations in LM production 495 
occurred, the magnitude of which grew in response to highly proinflammatory stimuli. We also report the 496 
production of several SPMs by hBMSCs. Most importantly, with exogenous PUFA supplementation, we are 497 
able to induce profound changes in the downstream SPMs functioning in the resolution of inflammation. At a 498 
practical level, this study highlights the impact of the external fatty acid milieu during cell culture, which is 499 
currently underestimated in standard cell culture mediums lacking PUFAs such as EPA and DHA. The 500 
supplementation of PUFAs into the cell culture medium provides a natural, safe and convenient method to 501 
modify MSCs and MSC-EVs rather than undergoing genetic manipulations of the cells [76]. Thus, the PUFA 502 
supplementation approach during cell culture should be considered as an improvement of clinical MSC and 503 
MSC-EV therapy products with a more potent proresolving phenotype.  504 
 505 
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Figure 1. Supplemented PUFAs alter the fatty acid profile of hBMSCs. hBMSCs were supplemented with AA 764 
(A), EPA (B), or DHA (C) for 2, 6, or 24 h and the fatty acid profile was analyzed by gas chromatography. The 765 
results are expressed as medians with ranges and as molar percentages (mol%); n = 3 experimental replicates 766 
per group; *, p < 0.05 using Jonckheere-Terpstra test for testing the trends.   767 
  768 
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 769 
 770 
 771 
Figure 2. The incorporation dynamics of supplemented PUFAs differ between hBMSC membrane PLs. 772 
hBMSCs were supplemented with AA, EPA, or DHA for 2, 6, or 24 h and the consequent phospholipidome 773 
changes were analyzed by ESI-MS/MS. Principal component analysis (PCA) was conducted for the species 774 
profiles of each specified PL class, n = 8 (control), n = 5 (AA and DHA), or n = 3 (EPA) experimental 775 
replicates per group. PC, phosphatidylcholine; PE, phosphatidylethanolamine; PS, phosphatidylserine. 776 
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Figure 3. Characterization of hBMSC-EVs. hBMSCs were supplemented with AA, EPA, or DHA for 24 h, 779 
incubated in serum-free medium for 48 h, and EVs were collected via ultracentrifugation. The particle 780 
concentration per 106 hBMSCs (A) and the size distribution of the particles (B) in hBMSC-EV samples were 781 
analyzed by Nanoparticle Tracking Analysis; n = 3 biological replicates per group. The expression of CD9, 782 
CD63, and CD73 was analyzed from control EVs by Western blotting (C).  783 
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 787 
Figure 4. PUFA modifications of hBMSC PL membranes are transferred to hBMSC-EVs. The phospholipid 788 
profiles of hBMSCs (A) and hBMSC-EVs (B). Cells were supplemented with AA, EPA, or DHA for 24 h and 789 
then incubated for 48 h in serum-free medium. The hBMSC-EVs were collected from the cell culture medium 790 
via ultracentrifugation, and both EVs and cells were analyzed for the PL species profiles by ESI-MS/MS. The 791 
results are expressed as medians with ranges and as molar percentages (mol%), showing PL species with greater 792 
than 1 mol%; n = 3 biological replicates per group, except for PS AA n = 2. PC, phosphatidylcholine; PE, 793 
phosphatidylethanolamine; PS, phosphatidylserine; SM, sphingomyelin. 794 
 795 
 796 
 32 
 
 797 
Figure 5. Representative multiple reaction monitoring chromatograms for the identified AA, EPA, and DHA 798 
metabolomes from the hBMSC incubations (A). Tandem mass spectrometry fragmentation spectra employed in 799 
the identification of resolvin (Rv)D4; peaks assigned to bolded m/z values indicate backbone breaks of the 800 
molecule (B). Specific examples of PUFA metabolomes following supplementation. hBMSCs were 801 
supplemented with AA, EPA, or DHA for 24 h, incubated for 48 h in serum-free medium, and then analyzed by 802 
LC-MS/MS. The results are expressed as pg per incubation (incubation volume = 9 mL); n = 3 biological 803 
replicates per group (C).  804 
 805 
 806 
 807 
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 808 
Figure 6. Incorporated PUFAs alter the downstream lipid mediator profile of hBMSCs. Principal component 809 
analysis of AA, EPA, and DHA metabolomes identified from the hBMSC incubations supplemented with AA, 810 
EPA, DHA, or control treatment, and then incubated for 48 h in serum-free medium, n = 3 biological replicates 811 
per group. 812 
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 813 
Figure 7. hBMSC lipid mediator profiles are regulated in a stimulus-dependent manner. hBMSCs were 814 
supplemented with AA or DHA for 24 h. The cells were then incubated with either TGF-β1 5 ng/mL and IL-10 815 
10 ng/mL (Condition 1); IFN-γ 25 ng/mL and LPS 10 ng/mL (Condition 2); IFN-γ 10 ng/mL and TNF-α 15 816 
ng/mL (Condition 3); or TNF-α 10 ng/mL, IL-1β 10 ng/mL, and LPS 100 ng/mL (Condition 4) for 48 h in 817 
serum-free medium, and analyzed by LC-MS/MS. The results are expressed as Fold change compared to the 818 
corresponding non-stimulated control; n = 3 biological replicates per group.  819 
 820 
